---
title: "Touyun Biotech Details Financing and Asset Moves to Address Audit Qualification and Support Growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271200522.md"
description: "Touyun Biotech Group Limited has announced measures to address an audit disclaimer and support growth, including expanding its health products portfolio and strengthening distribution channels. The company has secured a sales consortium commitment to purchase RMB1 billion of products and deferred repayments of HK$121.8 million from stakeholders. Additionally, it has obtained over HK$54 million in new loans and is negotiating extensions on existing loans. These actions aim to stabilize working capital and reduce audit qualifications. The latest analyst rating for the stock is a Sell with a price target of HK$0.20."
datetime: "2025-12-31T09:42:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271200522.md)
  - [en](https://longbridge.com/en/news/271200522.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271200522.md)
---

# Touyun Biotech Details Financing and Asset Moves to Address Audit Qualification and Support Growth

### Claim 70% Off TipRanks This Holiday Season

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

China Touyun Tech Group ( (HK:1332) ) just unveiled an announcement.

Touyun Biotech Group Limited has outlined a series of measures to address an audit disclaimer of opinion and alleviate going-concern uncertainties, centering on expanding its health products portfolio, strengthening distribution channels, and shoring up liquidity. The Group is rolling out new health products aimed at different customer segments, pursuing collaborations with supermarket chains and key opinion leaders, and has secured a strategic cooperation under which a sales consortium has committed to purchase at least RMB1 billion of Chlamydomonas reinhardtii products between 2026 and 2028. To reinforce its financial position, major stakeholders have deferred repayment of approximately HK$121.8 million of amounts due to them, the Company has obtained new loans totaling over HK$54 million from related parties and other lenders, is negotiating extensions on RMB150 million of existing loans, and is raising cash and recording gains through disposals of non-core assets and shareholdings in a subsidiary. These steps are intended to stabilize working capital, reduce audit qualifications, and support the Group’s operational and market expansion efforts.

The most recent analyst rating on (HK:1332) stock is a Sell with a HK$0.20 price target. To see the full list of analyst forecasts on China Touyun Tech Group stock, see the HK:1332 Stock Forecast page.

**More about China Touyun Tech Group**

Touyun Biotech Group Limited is a Hong Kong-listed group engaged in the biotechnology and health products sector, focusing on developing and selling new health products to a growing, health-conscious customer base. Through its subsidiary Shanxi Touyun Biotechnology Co., Ltd., the Group also produces Chlamydomonas reinhardtii and related products for distribution via domestic sales channels and strategic partners in mainland China.

**Average Trading Volume:** 4,867,637

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$589.2M

Learn more about 1332 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01332.HK](https://longbridge.com/en/quote/01332.HK.md)

## Related News & Research

- [Hisense Home Appliances Deploys RMB1.81 Billion into Chongqing Trust Wealth Products](https://longbridge.com/en/news/286888326.md)
- [NYC Health and Hospitals says hackers stole medical data and fingerprints during breach affecting at least 1.8 million people](https://longbridge.com/en/news/286799449.md)
- [03:00 ETHuion lanza la libreta electrónica Huion Note E: Productividad accesible para empresas y creativos](https://longbridge.com/en/news/287020642.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [Quirónsalud Madrid hospital conducts nearly 300 clinical trials annually](https://longbridge.com/en/news/287058598.md)